THE WEAK LINK IN THE DRUG-SAFETY CHAIN: DOCTORS.

Explores drug prescribing errors committed by physicians and its implications for the pharmaceutical industry in the United States. Withdrawal of Janseen Pharmaceutical Products LP's Propulsid from the market due to its risks; Order by United States Food and Drug Administration (FDA) to pull out Warner-Lambert Co.'s diabetes drug Rezulin from the market because of concern over liver toxicity; Problems confronting FDA when alerting physicians when restrictions are toughened after a drug has been approved.